Galecto Inc
GLTO - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$353.18M
Close$
$12.19
43.5% downside
Current Fair Value
43.5% downsideOvervalued by 43.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $353.18 Million |
|---|---|
| Enterprise Value | $-187,336,720.00 |
| Earnings per Share | $-152.99 |
| Beta | 1.6 |
| Outstanding Shares | 16,366,000 |
Return
| Return on Equity | -50.93% |
|---|---|
| Return on Assets | -48.35% |
| Return on Invested Capital | -18.67% |
Valuation & Multiples
| P/E Ratio | -0.17 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | 0.7 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.16 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.45
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Galecto Inc
28 employees
CEO: Jennifer A. Jarrett
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leadi...